Brian Jacoby

发表

P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS

R. Schlenk, S. Verstovsek, D. Cilloni, 2023, HemaSphere.

Galectin-3: therapeutic targeting in liver disease

Massimo Pinzani, D. Tonev, A. C. Mackinnon, 2023, Expert opinion on therapeutic targets.